Sarah Baker, Linden Lechner, Mitchell Liu, Jee Suk Chang, Ella Mae Cruz-Lim, Ben Mou, Will Jiang, Alanah Bergman, Devin Schellenberg, Abraham Alexander, Tanya Berrang, Andrew Bang, Nick Chng, Quinn Matthews, Hannah Carolan, Fred Hsu, Stacey Miller, Siavash Atrchian, Elisa Chan, Clement Ho, Islam Mohamed, Angela Lin, Vicky Huang, Ante Mestrovic, Derek Hyde, Chad Lund, Howard Pai, Boris Valev, Shilo Lefresne, Gregory Arbour, Irene Yu, Scott Tyldesley, Rob A Olson
PURPOSE: The optimal sequencing of local and systemic therapy for oligometastatic cancer has not been established. This study retrospectively compared progression-free survival (PFS), overall survival (OS), and SABR-related toxicity between upfront versus delay of systemic treatment until progression in patients in the SABR-5 trial. METHODS AND MATERIALS: The single-arm phase 2 SABR-5 trial accrued patients with up to 5 oligometastases across SABR-5 between November 2016 and July 2020...
April 1, 2024: International Journal of Radiation Oncology, Biology, Physics